David DiLillo

Company: Regeneron

Job title: Director, Immuno- Oncology

Seminars:

Targeting Alternative T Cell Effector Pathways to Enhance the Anti-Tumor Activity of CD3-Engaging Bispecific Antibodies 12:30 pm

– CD3-engaging bispecific antibodies drive potent anti-tumor activity in pre-clinical models as well as in patients – However, not all patients respond to therapy and many relapse after initially responding – Here, we describe novel therapeutics that engage alternative T cell signaling pathways and demonstrate combinatorial anti-tumor effects in high-bar pre-clinical modelsRead more

day: Day Two